December 2016
-
Lindal Group has launched a new nasal actuator called Cyrano, which has a rounded asymmetric pyramidal shape. According to the company, the actuator shape preventing insertion of the device too far into the nose, and… Read more . . .
-
A joint venture of Cipla, Cooper Pharma, and the Pharmaceutical Institute has constructed a new metered dose inhaler manufacturing plant in a suburb of Rabat, Morocco that opened officially as of October 14, 2018. The… Read more . . .
-
Seurat Therapeutics, a start-up biotech based at the University of Chicago, has received a grant of almost $510,000 from the National Institute of Neurological Disorders and Stroke for development of its intranasal IGF-1 for the… Read more . . .
-
According to AstraZeneca, the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion regarding the marketing authorization application for the company’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of… Read more . . .
-
Auris Medical has announced results from a second Phase 1 study of its intranasal betahistine in 72 healthy volunteers that demonstrated superior bioavailability compared to oral betahistine for 4 doses of the nasal formulation, with… Read more . . .
-
Dry powder inhaler developer Iconovo has announced a partnership with McMaster University for development of a dry powder tuberculosis vaccine to be delivered via Iconovo’s ICOone single-dose DPI. According to the company, the ICOone inhaler… Read more . . .
-
Secarna Pharmaceuticals has announced that the Inhaled Nanocarriers with Antisense Therapy for lung fibrosis (INAT) project has received a 3-year grant to fund from the ERA-Net Cofund EuroNanoMed3, part of the EC’s Horizon 2020 Framework… Read more . . .
-
Proveris Scientific, which offers a variety of products and services related to aerosol characterization, has achieved certification to the ISO 9001:2015 quality standard through October 2021, the company said. TUV Rheinland of North America, which… Read more . . .
-
The FDA has approved labeling and indication changes for Boehringer Ingelheim’s Stiolto Respimat tiotropium/olodaterol SMI, adding data about reductions in COPD exacerbations to the label. Stiolto Respimat (marketed in Europe as Spiolto Respimat) was initially… Read more . . .
-
Janssen Pharmaceutical has submitted an MAA to the EMA for its esketamine nasal spray for the treatment of treatment-resistant depression in adults with major depressive disorder, the company said. Janssen submitted an NDA for the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland